01830nam a2200193 a 450000100080000000500110000800800410001910000190006024501390007926001140021852011730033265000260150565300150153165300100154665300250155665300140158170000200159570000210161510480182023-06-23       2007    bl uuuu     u00u1 u    #d1 aZAFALON, L. F.  aSubclinical mastitis caused by staphylococcus aureusbanalysis cost benefit of antibiotic therapy in lactating.h[electronic resource]  aIn: INTERNATIONAL DAIRY HOUSING CONFERENCE, 6., 2007, Mineapolis, USA. Proceedings... Mineapolis: ASABEc2007  aThe cost benefit analysis of treatment ofbovine subclinical mastitis caused by S. aureus was evaluated. Two hundred and seventy udder quarters with subclinical mastitis and healthy were selected in four groups, in conformity to lactational slage and Wilh lhe trealment or noto Group I included lreated animais 10 to 60 days in milk; group 2 included trealed animais 61 days in milk untilrwo monlhs before lhe end oflactation; group 3 included animais not lreated 10 to 60 days in milk; group 4 included animais not lrealed from 61 days in milk unlil two monlhs before lhe end of lactalion. Trealment wilh gentamicin (150 mgi was accomplished by inlramammary doses, once a day, after sensitivity tests. The mammary quarters were evaluated after 30 days again. The costs with lhe treatment were calculaled considering a S. aureus prevalence of 5%, expenses with anlibiotic, loss in milk, lests of sensitivity and workload. There was loss of income of 2% and 14% in lhe groups I and 2, respeclively, when compared Wilh lhe incomes before trealment. In such case, the trealment of bovine subclinical maslilis by s. aurcus in lhe laclalion was economical/y nol practicable.  aStaphylococcus Aureus  aAntibiatic  acosts  aSubclinical maslitis  aTreatmenl1 aNADER FILHO, A.1 aMATARAZZO, S. V.